Trial · NCT03240133
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 1: Berotralstat 750 mg - Predose | 13.96 | Standard Deviation 9.84 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 1: Placebo - Pre-dose | 15.04 | Standard Deviation 11.90 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 1: Berotralstat 750 mg - 4hr Post-dose | 10.54 | Standard Deviation 11.39 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 1: Placebo - 4hr Post-dose | 18.42 | Standard Deviation 14.19 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 2: Berotralstat 500 mg - Predose | 17.69 | Standard Deviation 15.25 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 2: Placebo - Pre-dose | 13.48 | Standard Deviation 16.11 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 2: Berotralstat 500 mg - 4hr Post-dose | 11.31 | Standard Deviation 15.75 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 2: Placebo - 4hr Post-dose | 9.26 | Standard Deviation 11.53 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 3: Berotralstat 250 mg - Predose | 14.57 | Standard Deviation 11.78 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 3: Placebo - Pre-dose | 11.33 | Standard Deviation 10.17 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 3: Berotralstat 250 mg - 4hr Post-dose | 10.92 | Standard Deviation 10.31 | VAS score - millimeters | |
| Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score | Part 3: Placebo - 4hr Post-dose | 9.21 | Standard Deviation 9.67 | VAS score - millimeters | |
| Percentage of Attacks Treated With Standard of Care Acute Attack Medication (SOC-Rx) Through 24 Hours | Part 1: Berotralstat 750 mg | 29.7 | Percentage attacks treated with SOC-Rx | ||
| Percentage of Attacks Treated With Standard of Care Acute Attack Medication (SOC-Rx) Through 24 Hours | Part 1: Placebo | 61.3 | Percentage attacks treated with SOC-Rx | ||
| Percentage of Attacks Treated With Standard of Care Acute Attack Medication (SOC-Rx) Through 24 Hours | Part 2: Berotralstat 500 mg | 32.0 | Percentage attacks treated with SOC-Rx | ||
| Percentage of Attacks Treated With Standard of Care Acute Attack Medication (SOC-Rx) Through 24 Hours | Part 2: Placebo | 45.5 | Percentage attacks treated with SOC-Rx | ||
| Percentage of Attacks Treated With Standard of Care Acute Attack Medication (SOC-Rx) Through 24 Hours | Part 3: Berotralstat 250 mg | 38.1 | Percentage attacks treated with SOC-Rx | ||
| Percentage of Attacks Treated With Standard of Care Acute Attack Medication (SOC-Rx) Through 24 Hours | Part 3: Placebo | 45.5 | Percentage attacks treated with SOC-Rx |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03240133/results